Digitoxin is a cardiac glycoside used in the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.
- Mechanism
- Curator reviewed
Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digitoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
- Primary indication
- For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.Curator reviewed · 5 structured indications
- Formula / weight
- C41H64O13 · 764.9391 g/mol (avg)
- First approval
- Canada, 1951
- Also known as
- Digitoksin · Digitoxoside
- Code names
- NSC-7529
Resolves to
WDJUZGPOPHTGOT-XUDUSOBPSA-NSMILES[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Digitoxin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account